ADC Payloads and Linkers

Antibody drug conjugate (ADC) services support the development and manufacturing of key ADC components, including linkers and cytotoxic payloads. At SK pharmteco, these services focus on process development, high-potency APIs chemistry, purification, analytical and manufacturing capabilities needed to support ADC programs from early development through commercial supply.

ADC payload development involves the synthesis and purification of highly potent cytotoxic small molecules designed to eliminate targeted cancer cells. These compounds require specialized containment systems and expertise to handle highly potent APIs (HPAPIs). SK pharmteco applies experience in HPAPI synthesis and chromatographic purification to support payload development and manufacturing.

Linkers connect the cytotoxic payload to the monoclonal antibody and control how the payload is released in the body. Linker stability, release mechanisms, and compatibility with the antibody are important considerations during ADC drug development.
SK pharmteco manufactures linkers to support ADC programs.

ADC manufacturing requires expertise in handling highly potent APIs, containment systems, purification technologies, and analytical testing. Facilities must be designed to safely handle hazardous substances while minimizing exposure and maintaining product quality and consistency. SK pharmteco supports ADC payload and linker development and manufacturing with specialized capabilities and facilities.

ADC payloads are extremely hazardous molecules that must be handled in controlled environments to protect personnel, prevent cross-contamination and maintain product quality. Facilities designed for low occupational exposure limits (OELs) allow manufacturers to safely develop and produce these compounds. SK pharmteco operates facilities designed to support HPAPI and ADC payload manufacturing under controlled containment conditions with OELs as low as 10 ng/m³.

Yes. ADC programs typically progress from small-scale development to larger clinical and commercial manufacturing batches. This requires scalable processes, reliable supply chains, and specialized facilities and the expertise to successfully manufacture. SK pharmteco provides payload and linker development and manufacturing capabilities designed to support ADC programs as they advance.

ADC development involves complex chemistries, including antibody production, linker and payload synthesis, and bioconjugation to produce a complete and effective final product. Coordinating these activities helps reduce development complexity and technology transfer challenges.

Companies developing ADC therapies should assess CDMO partners with proven experience with HPAPI chemistry, containment strategies, analytical support, and scalability experience. SK pharmteco provides the technical expertise and capabilities to support your ADC program from early phase to commercial manufacturing.